These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22859605)

  • 1. Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.
    Ding ZC; Huang L; Blazar BR; Yagita H; Mellor AL; Munn DH; Zhou G
    Blood; 2012 Sep; 120(11):2229-39. PubMed ID: 22859605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.
    Ding ZC; Blazar BR; Mellor AL; Munn DH; Zhou G
    Blood; 2010 Mar; 115(12):2397-406. PubMed ID: 20118405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
    Ding ZC; Lu X; Yu M; Lemos H; Huang L; Chandler P; Liu K; Walters M; Krasinski A; Mack M; Blazar BR; Mellor AL; Munn DH; Zhou G
    Cancer Res; 2014 Jul; 74(13):3441-53. PubMed ID: 24780756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
    Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
    J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
    Houot R; Levy R
    Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.
    Ding ZC; Zhou G
    Clin Dev Immunol; 2012; 2012():890178. PubMed ID: 22400040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells.
    Chamoto K; Tsuji T; Funamoto H; Kosaka A; Matsuzaki J; Sato T; Abe H; Fujio K; Yamamoto K; Kitamura T; Takeshima T; Togashi Y; Nishimura T
    Cancer Res; 2004 Jan; 64(1):386-90. PubMed ID: 14729649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines targeting helper T cells for cancer immunotherapy.
    Melssen M; Slingluff CL
    Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.
    Sasikumar PG; Ramachandra RK; Adurthi S; Dhudashiya AA; Vadlamani S; Vemula K; Vunnum S; Satyam LK; Samiulla DS; Subbarao K; Nair R; Shrimali R; Gowda N; Ramachandra M
    Mol Cancer Ther; 2019 Jun; 18(6):1081-1091. PubMed ID: 31015307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent STAT5 activation reprograms the epigenetic landscape in CD4
    Ding ZC; Shi H; Aboelella NS; Fesenkova K; Park EJ; Liu Z; Pei L; Li J; McIndoe RA; Xu H; Piazza GA; Blazar BR; Munn DH; Zhou G
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33127608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.